NCT00045201 2026-03-18
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
12 trialsNCT01375829 2026-03-18
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01281176 2025-10-20
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT00813423 2023-08-02
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00334789 2018-04-03
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01061749 2016-01-25
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00888134 2016-01-15
Selumetinib in Cancers With BRAF Mutations
National Cancer Institute (NCI)
Phase 2 Completed
NCT01093092 2016-01-12
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01625156 2015-10-20
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01154426 2015-07-02
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00217373 2015-04-20
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
National Cancer Institute (NCI)
Phase 1 Completed
NCT01218620 2014-12-23
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed